These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 38445848)

  • 41. Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
    Darvishian M; Janjua NZ; Chong M; Cook D; Samji H; Butt ZA; Yu A; Alvarez M; Yoshida E; Ramji A; Wong J; Woods R; Tyndall M; Krajden M
    J Viral Hepat; 2018 Dec; 25(12):1481-1492. PubMed ID: 30047609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
    Durham DP; Skrip LA; Bruce RD; Vilarinho S; Elbasha EH; Galvani AP; Townsend JP
    Clin Infect Dis; 2016 Feb; 62(3):298-304. PubMed ID: 26628566
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.
    Park H; Jiang X; Song HJ; Lo Re V; Childs-Kean LM; Lo-Ciganic WH; Cook RL; Nelson DR
    Hepatology; 2021 Aug; 74(2):566-581. PubMed ID: 33544904
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Population impact of direct-acting antiviral treatment on new presentations of hepatitis C-related decompensated cirrhosis: a national record-linkage study.
    Hutchinson SJ; Valerio H; McDonald SA; Yeung A; Pollock K; Smith S; Barclay S; Dillon JF; Fox R; Bramley P; Fraser A; Kennedy N; Gunson RN; Templeton K; Innes H; McLeod A; Weir A; Hayes PC; Goldberg D
    Gut; 2020 Dec; 69(12):2223-2231. PubMed ID: 32217640
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The dynamic effect of direct-acting antiviral treatments on the risk of hepatocellular carcinoma in patients with cirrhosis and chronic hepatitis C.
    Lusivika-Nzinga C; Fontaine H; Dorival C; Simony M; Pol S; Carrat F;
    J Viral Hepat; 2019 Dec; 26(12):1489-1492. PubMed ID: 31386252
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The current and future burden of hepatitis B in Switzerland: a modelling study.
    Negro F; Müllhaupt B; Semela D; Blach S; Bruggmann P; De Gottardi A; Dufour JF; Fraga M; Galante A; Razavi H; Vieira Barbosa J; Razavi-Shearer D
    Swiss Med Wkly; 2023 Jun; 153():40086. PubMed ID: 37410921
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Burden of disease and cost of chronic hepatitis C infection in Canada.
    Myers RP; Krajden M; Bilodeau M; Kaita K; Marotta P; Peltekian K; Ramji A; Estes C; Razavi H; Sherman M
    Can J Gastroenterol Hepatol; 2014 May; 28(5):243-50. PubMed ID: 24839620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The impact of SVR from direct-acting antiviral- and interferon-based treatments for HCV on hepatocellular carcinoma risk.
    Janjua NZ; Wong S; Darvishian M; Butt ZA; Yu A; Binka M; Alvarez M; Woods R; Yoshida EM; Ramji A; Feld J; Krajden M
    J Viral Hepat; 2020 Aug; 27(8):781-793. PubMed ID: 32187430
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world impact following initiation of interferon-free hepatitis C regimens on liver-related outcomes and all-cause mortality among patients with compensated cirrhosis.
    McDonald SA; Pollock KG; Barclay ST; Goldberg DJ; Bathgate A; Bramley P; Dillon JF; Fraser A; Innes HA; Kennedy N; Morris J; Went A; Hayes PC; Hutchinson SJ
    J Viral Hepat; 2020 Mar; 27(3):270-280. PubMed ID: 31696575
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Reconstructing and predicting the hepatitis C virus epidemic in Greece: increasing trends of cirrhosis and hepatocellular carcinoma despite the decline in incidence of HCV infection.
    Sypsa V; Touloumi G; Tassopoulos NC; Ketikoglou I; Vafiadis I; Hatzis G; Tsantoulas D; Akriviadis E; Delladetsima J; Demonakou M; Hatzakis A
    J Viral Hepat; 2004 Jul; 11(4):366-74. PubMed ID: 15230860
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Shift in disparities in hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    Janjua NZ; Islam N; Wong J; Yoshida EM; Ramji A; Samji H; Butt ZA; Chong M; Cook D; Alvarez M; Darvishian M; Tyndall M; Krajden M
    J Viral Hepat; 2017 Aug; 24(8):624-630. PubMed ID: 28130810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. National Hepatitis C estimates: Incidence, prevalence, undiagnosed proportion and treatment, Canada, 2019.
    Popovic N; Williams A; Périnet S; Campeau L; Yang Q; Zhang F; Yan P; Feld J; Janjua N; Klein M; Krajden M; Wong W; Cox J
    Can Commun Dis Rep; 2022 Nov; 48(11-12):540-549. PubMed ID: 38222827
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gaps in hepatitis C virus prevention and care for HIV-hepatitis C virus co-infected people who inject drugs in Canada.
    Lanièce Delaunay C; Maheu-Giroux M; Marathe G; Saeed S; Martel-Laferrière V; Cooper CL; Walmsley S; Cox J; Wong A; Klein MB;
    Int J Drug Policy; 2022 May; 103():103627. PubMed ID: 35218989
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Future trends of HCV-related cirrhosis and hepatocellular carcinoma under the currently available treatments.
    Sypsa V; Touloumi G; Papatheodoridis GV; Tassopoulos NC; Ketikoglou I; Vafiadis I; Hatzis G; Tsantoulas D; Akriviadis E; Koutsounas S; Hatzakis A
    J Viral Hepat; 2005 Sep; 12(5):543-50. PubMed ID: 16108772
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Planning the hepatitis C virus elimination in Cyprus: A modeling study.
    Gountas I; Yiasemi I; Kyprianou E; Mina C; Georgiou C; Katsioloudes P; Kouroufexi A; Demetriou A; Xenofontos E; Nikolopoulos G
    World J Gastroenterol; 2021 Aug; 27(31):5219-5231. PubMed ID: 34497446
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Estimated prevalence of undiagnosed HCV infected individuals in Italy: A mathematical model by route of transmission and fibrosis progression.
    Kondili LA; Andreoni M; Alberti A; Lobello S; Babudieri S; Roscini AS; Merolla R; Marrocco W; Craxì A
    Epidemics; 2021 Mar; 34():100442. PubMed ID: 33607538
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
    Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
    Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Profile and value of FIB-4 in patients with dual chronic hepatitis C and B.
    Liu CJ; Tseng TC; Yang WT; Su TH; Yang HC; Liu CH; Chen PJ; Chen DS; Kao JH
    J Gastroenterol Hepatol; 2019 Feb; 34(2):410-417. PubMed ID: 30151861
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Predicted effects of treatment for HCV infection vary among European countries.
    Deuffic-Burban S; Deltenre P; Buti M; Stroffolini T; Parkes J; Mühlberger N; Siebert U; Moreno C; Hatzakis A; Rosenberg W; Zeuzem S; Mathurin P
    Gastroenterology; 2012 Oct; 143(4):974-85.e14. PubMed ID: 22863764
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Characteristics and Treatment Rate of Patients With Hepatitis C Virus Infection in the Direct-Acting Antiviral Era and During the COVID-19 Pandemic in the United States.
    Nguyen VH; Kam L; Yeo YH; Huang DQ; Henry L; Cheung R; Nguyen MH
    JAMA Netw Open; 2022 Dec; 5(12):e2245424. PubMed ID: 36477481
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.